Evidence map›Paper›PMID 30613329›Full record

ArticleACS medicinal chemistry letters2018

Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors.

Kap-Sun Yeung, Brett R Beno, Kathy Mosure, Juliang Zhu, Katherine A Grant-Young, Kyle Parcella, Prakash Anjanappa, Rajesh Onkardas Bora, Kumaravel Selvakumar, Ying-Kai Wang and 17 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Hidden Interactions: Quantum Perspectives in Drug Design.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 2 countries.

Kap-Sun YeungBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Brett R BenoBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Kathy MosureBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Juliang ZhuBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Katherine A Grant-YoungBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Kyle ParcellaBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Prakash AnjanappaDepartment of Discovery Chemistry, Biocon Bristol-Myers Squibb Research and Development Center, Biocon Park, Jigani Link Road, Bommasandra IV, Bangalore 560099, India.
Rajesh Onkardas BoraDepartment of Discovery Chemistry, Biocon Bristol-Myers Squibb Research and Development Center, Biocon Park, Jigani Link Road, Bommasandra IV, Bangalore 560099, India.
Kumaravel SelvakumarDepartment of Discovery Chemistry, Biocon Bristol-Myers Squibb Research and Development Center, Biocon Park, Jigani Link Road, Bommasandra IV, Bangalore 560099, India.
Ying-Kai WangBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Hua FangBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Rudolph KrauseBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Karen RigatBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Mengping LiuBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Julie LemmBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Steven SheriffBristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Mark WitmerBristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Jeffrey TredupBristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Adam JardelBristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Kevin KishBristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States.
Dawn ParkerBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Roy HaskellBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Kenneth SantoneBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Nicholas A MeanwellBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Matthew G SoarsBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Susan B RobertsBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
John F KadowBristol-Myers Squibb Research and Development, P.O. Box 5100, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Bristol-Myers Squibb (United States) · USBristol-Myers Squibb (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In solving the P-gp and BCRP transporter-mediated efflux issue in a series of benzofuran-derived pan-genotypic palm site inhibitors of the hepatitis C virus NS5B replicase, it was found that close attention to physicochemical properties was essential. In these compounds, where both molecular weight (MW >579) and TPSA (>110 Å

Identifiers

PMID30613329
PMCPMC6295864
OpenAlexW2899716776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.